Literature DB >> 20709132

The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats.

Takeshi Kunimatsu1, Juki Kimura, Hitoshi Funabashi, Tadashi Inoue, Takaki Seki.   

Abstract

The main objective of this study was to evaluate the effects of the antipsychotic drugs haloperidol (HAL) and chlorpromazine (CPZ) on bone mineral density (BMD) in female rats and to examine the relationship between the effects on bone and reproductive organs or hormone concentrations. Female rats were orally administered HAL (2 or 10 mg/kg) or CPZ (25 or 50 mg/kg) once daily (7 days/week) for 6 months resulting in a significant increase in prolactin. Hyperprolactinemia resulted in enlarged corpora lutea in the ovary, because prolactin has a luteotropic activity. Thus, atrophy in the uterus, epithelial mucification in the vagina and continuous diestrus stages were observed. These events in the reproductive organs induced a decrease in estradiol, elevation of biochemical markers of bone metabolism, significant reductions of BMD in trabecular bone of the femur and decreased trabecular bone in the femur. The bone loss is associated with an increase in bone resorption due to decreased estradiol derived from the luteotropic activity of prolactin. The mechanism of dopamine blockers to induce bone loss in female rats is considered to be rodent specific because the luteotropic effects of prolactin are confined primarily to rodents. Also, it appears that chronic hyperprolactinemia and maintained corpora lutea leading to bone loss are commonly inducible in female rats receiving long-term treatment with antipsychotic drugs possessing dopamine D2 receptor antagonist activity.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709132     DOI: 10.1016/j.yrtph.2010.08.001

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  12 in total

1.  Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.

Authors:  Chadi A Calarge; Stephanie D Ivins; Katherine J Motyl; Amal A Shibli-Rahhal; Michael M Bliziotes; Janet A Schlechte
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

Review 2.  Osteoporosis and fracture risk in people with schizophrenia.

Authors:  Taishiro Kishimoto; Marc De Hert; Harold E Carlson; Peter Manu; Christoph U Correll
Journal:  Curr Opin Psychiatry       Date:  2012-09       Impact factor: 4.741

3.  Screening for angiogenic inhibitors in zebrafish to evaluate a predictive model for developmental vascular toxicity.

Authors:  Tamara Tal; Claire Kilty; Andrew Smith; Carlie LaLone; Brendán Kennedy; Alan Tennant; Catherine W McCollum; Maria Bondesson; Thomas Knudsen; Stephanie Padilla; Nicole Kleinstreuer
Journal:  Reprod Toxicol       Date:  2016-12-19       Impact factor: 3.143

4.  Expression of prolactin receptors in the duodenum, kidneys and skeletal system during physiological and sulpiride-induced hyperprolactinaemia.

Authors:  Danijela Radojkovic; Milica Pesic; Milan Radojkovic; Dragan Dimic; Marija Vukelic Nikolic; Tatjana Jevtovic Stoimenov; Sasa Radenkovic; Milena Velojic Golubovic; Tatjana Radjenovic Petkovic; Slobodan Antic
Journal:  Endocrine       Date:  2018-08-24       Impact factor: 3.633

Review 5.  Brains, bones, and aging: psychotropic medications and bone health among older adults.

Authors:  Monique J Brown; Briana Mezuk
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

6.  Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment.

Authors:  Jeffrey R Bishop; Leah H Rubin; James L Reilly; Mani N Pavuluri; John A Sweeney
Journal:  Ther Adv Psychopharmacol       Date:  2012-06

Review 7.  Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications.

Authors:  Matthieu P K Crews; Oliver D Howes
Journal:  Hum Psychopharmacol       Date:  2012-01-09       Impact factor: 1.672

8.  Chlorpromazine-Induced Hyperprolactinemia on Rat's Uterus.

Authors:  Zahra Zamani; Samad Zare; Rajabali Sadrkhanlou; Abbas Ahmadi; Elham Movahed
Journal:  Iran Biomed J       Date:  2015-08-04

9.  The Effects of Chlorpromazine on Reproductive System and Function in Female Rats.

Authors:  Zahra Zamani; Samad Zare; Rajabali Sadrkhanlou; Abbas Ahmadi; Elham Movahed
Journal:  Int J Fertil Steril       Date:  2015-10-31

10.  Factors associated with decreased bone mineral density in postmenopausal women with schizophrenia.

Authors:  Ying Liang; Jian Huang; Jing-bin Tian; Yuan-yuan Cao; Guo-ling Zhang; Chun-gang Wang; Ying Cao; Jian-rong Li
Journal:  Clin Interv Aging       Date:  2016-02-17       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.